Back to Search Start Over

Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury.

Authors :
Wong JK
Deuschl G
Wolke R
Bergman H
Muthuraman M
Groppa S
Sheth SA
Bronte-Stewart HM
Wilkins KB
Petrucci MN
Lambert E
Kehnemouyi Y
Starr PA
Little S
Anso J
Gilron R
Poree L
Kalamangalam GP
Worrell GA
Miller KJ
Schiff ND
Butson CR
Henderson JM
Judy JW
Ramirez-Zamora A
Foote KD
Silburn PA
Li L
Oyama G
Kamo H
Sekimoto S
Hattori N
Giordano JJ
DiEuliis D
Shook JR
Doughtery DD
Widge AS
Mayberg HS
Cha J
Choi K
Heisig S
Obatusin M
Opri E
Kaufman SB
Shirvalkar P
Rozell CJ
Alagapan S
Raike RS
Bokil H
Green D
Okun MS
Source :
Frontiers in human neuroscience [Front Hum Neurosci] 2022 Mar 04; Vol. 16, pp. 813387. Date of Electronic Publication: 2022 Mar 04 (Print Publication: 2022).
Publication Year :
2022

Abstract

DBS Think Tank IX was held on August 25-27, 2021 in Orlando FL with US based participants largely in person and overseas participants joining by video conferencing technology. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging deep brain stimulation (DBS) technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank IX speakers was that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. After collectively sharing our experiences, it was estimated that globally more than 230,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. As such, this year's meeting was focused on advances in the following areas: neuromodulation in Europe, Asia and Australia; cutting-edge technologies, neuroethics, interventional psychiatry, adaptive DBS, neuromodulation for pain, network neuromodulation for epilepsy and neuromodulation for traumatic brain injury.<br />Competing Interests: RR was employed by Medtronic, Inc. HBo was employed by Boston Scientific Neuromodulation Corporation. DG was employed by the NeuroPace, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Wong, Deuschl, Wolke, Bergman, Muthuraman, Groppa, Sheth, Bronte-Stewart, Wilkins, Petrucci, Lambert, Kehnemouyi, Starr, Little, Anso, Gilron, Poree, Kalamangalam, Worrell, Miller, Schiff, Butson, Henderson, Judy, Ramirez-Zamora, Foote, Silburn, Li, Oyama, Kamo, Sekimoto, Hattori, Giordano, DiEuliis, Shook, Doughtery, Widge, Mayberg, Cha, Choi, Heisig, Obatusin, Opri, Kaufman, Shirvalkar, Rozell, Alagapan, Raike, Bokil, Green and Okun.)

Details

Language :
English
ISSN :
1662-5161
Volume :
16
Database :
MEDLINE
Journal :
Frontiers in human neuroscience
Publication Type :
Academic Journal
Accession number :
35308605
Full Text :
https://doi.org/10.3389/fnhum.2022.813387